Researchers at Stanford have leveraged spatial proteomic analysis to identify biomarkers with immediate implications for HER2-positive breast cancer treatment decision making and patient stratification.
Stanford researchers have formulated a statistical model to determine the risk of breast cancer recurrence with unprecedented accuracy in women 5 – 20 years after initial diagnosis.